All News
Believing is Doing (1.21.2022)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. These reports are about better outcomes in Lupus; fewer Gout flares with T2T and the power of belief.
Read Article
3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients
ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third
Read Article
Herpes Zoster Vaccination in Immunocompromised Adults
The CDC's Advisory Committee on Immunization Practices (ACIP) recently recommended and approved two doses of the recombinant zoster vaccine (RZV, AKA Shingrix) for prevention of herpes zoster and complications in immunodeficient or immunosuppressed adults aged ≥19 years.
Read Article
3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients
https://t.co/UXUryaQ7Fz https://t.co/p40xND4lVP
Links:
Dr. John Cush RheumNow ( View Tweet)
The CDC's Advisory Committee on Immunization Practices recently recommended & approved 2 doses of the recombinant zoster vaccine for prevention of herpes zoster and complications in immunodeficient/immunosuppressed adults aged ≥19 years.
https://t.co/nk4feoUO5B https://t.co/6fR33fG5xw
Links:
Dr. John Cush RheumNow ( View Tweet)
791 knee OA pts studied for progression after steroid (GC) (n=629) vs hyaluronic (HA) injxn (n=162). Knee OA progression was similar between groups for JSN (RR 1.00) & K/L grade (1.03); but IA GC had slightly lower TKR (HR 0.75 [CI 0.51–1.09]) https://t.co/74eg2Zvdy1 https://t.co/soXb7bdq6O
Links:
Dr. John Cush RheumNow ( View Tweet)
Yesterdays RheumNow Live Vote survey of 170 Rheumatologists, showed that 74-80% of Rheums are reporting shortages of IV tocilizumab (Actemra) -- TCZ listed by FDA site as a drug in shortage largely due to demand, Genentech says there is supply https://t.co/YAvR4vbVHV
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live Vote survey of 159 Rheumatologists shows, because of the Actemra Shortage, Rheums are either changing to subQ TCZ (45%), changing to other biologic or tsDMARD (33%) or waiting for resupply of TCZ (21%). https://t.co/zNeyRsYClD @CreakyJoints https://t.co/aGYO2fqw7J
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live vote Survey of 161 Rheums shows that in addition to a tocilizumab shortage the main drug shortage is for sulfasalazine (34%) https://t.co/uE856PbF2v @CreakyJoints https://t.co/eCLy3rpjoI
Links:
Dr. John Cush RheumNow ( View Tweet)
GWAS study in RA used to develop polygenic risk score (PRS) for Xray progression (training set = 500 and validated testing set= 740). Risk factors for severe XRAY progr = PRS (P=0.00019), female (P=0.0033), ACPA (P=0.0023), BMI (P=0.031) https://t.co/dwDSnTFUqs
Links:
Dr. John Cush RheumNow ( View Tweet)
Who is Your Glue?
Surely you have used or heard of “<the person> who was the glue that held the family together”.
Read on…
https://t.co/CRaWDQaZvk https://t.co/q8KFcxzzDG
Links:
Dr. John Cush RheumNow ( View Tweet)
Referral Rules for At-Risk Inflammatory Arthritis
https://t.co/p1sBNSmWF5 https://t.co/tk29UNPYdi
Links:
Dr. John Cush RheumNow ( View Tweet)
ONE MILLION DOWNLOADS!
We are excited to announce Dr.Cush and the RheumNow podcast recently hit one million downloads!
Thank you to all of our listeners-we appreciate you coming back week after week.
Find us each week where ever you get your podcasts.
https://t.co/AOJCMGZClJ https://t.co/3ImftCnqzw
Links:
Dr. John Cush RheumNow ( View Tweet)
The next generation of lupus therapies (esp in lupus nephritis) - belimumab, voclosporin , anifrolumab, obinutuzumab. Better trial designs, better organ endpoints, but yet these trials/results are limited by the high dose steroids in play.... https://t.co/48D9rI9EEH
Links:
Dr. John Cush RheumNow ( View Tweet)
How's the United States doing on boosters?
Trailing a long list of countries, including Serbia, Slovenia, and Lithuania
@OurWorldInData https://t.co/cOCVoyuqT3
Eric Topol EricTopol ( View Tweet)
UTSW Rheum Grand Rounds
New and concerning: sJIA associated lung disease - rare and associated w/ pulmonary HTN, alveolar proteinosis, high mortality. Unique features: clubbing, eosinophilia, TCZ anaphylaxis, Trisomy 21. Most were Rx w/ IL-1 > IL-6 inhibition @UTSWRheum https://t.co/aJaPurDSmJ
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - Dr. Nigrovic shows the efficacy of long acting IL-1 inhibition (canakinumab) and IL-6 (tocilizumab) in systemic JIA patients @UTSWRheum https://t.co/XdG8pAq1c4
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds
Treating STill's (sJIA) - early early use of anakinra yields best results (in remission and off steroids) - 91% if Anakinra started within the first 3 mos @UTSWRheum https://t.co/neozpYhJtM
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds
MAS occurs in 2-8% of Systemic JIA pts and has a high mortality (<40%); It is more frequent w/ onset in Years 1-4. Treatment - steroids, anakinra, etoposide or CsA & Rx infxn if present. Oh...dont stop the anakinra! @UTSWRheum https://t.co/09uQm3LURC
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds
IL-18 levels are elevated in systemic JIA, MAS and AOSD @UTSWRheum https://t.co/pIYKf4pods
Dr. John Cush RheumNow ( View Tweet)